Pulse Biosciences Inc. (PLSE)
NASDAQ: PLSE
· Real-Time Price · USD
19.29
0.30 (1.58%)
At close: Oct 03, 2025, 3:59 PM
19.20
-0.47%
After-hours: Oct 03, 2025, 06:44 PM EDT
1.58% (1D)
| Bid | 18.17 |
| Market Cap | 1.3B |
| Revenue (ttm) | 1.66M |
| Net Income (ttm) | -68.03M |
| EPS (ttm) | -1.1 |
| PE Ratio (ttm) | -17.54 |
| Forward PE | -13.19 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 20.89 |
| Volume | 501,527 |
| Avg. Volume (20D) | 194,616.3 |
| Open | 19.18 |
| Previous Close | 18.99 |
| Day's Range | 19.13 - 20.40 |
| 52-Week Range | 13.77 - 25.00 |
| Beta | 1.79 |
| Ex-Dividend Date | n/a |
About PLSE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PLSE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PLSE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsPulse Biosciences Inc. is scheduled to release its earnings on
Oct 29, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-0.46%
PLSE stock has given up its prior gain. Pulse Bios...
Unlock content with
Pro Subscription
4 weeks ago
-0.46%
Pulse Biosciences shares are trading higher after the company announced that the FDA granted approval for its Investigational Device Exemption, allowing Pulse Biosciences to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation.
2 months ago · businesswire.com
Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth ConferenceHAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today ...
